These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 29031769)

  • 1. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
    Pinto RA; Costa D; Morgado A; Pereira P; Charrua A; Silva J; Cruz F
    J Urol; 2018 Apr; 199(4):998-1003. PubMed ID: 29031769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome.
    Chuang YC; Kuo HC
    J Urol; 2017 Aug; 198(2):376-382. PubMed ID: 28202358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis.
    Pinto R; Lopes T; Silva J; Silva C; Dinis P; Cruz F
    J Urol; 2013 Feb; 189(2):548-53. PubMed ID: 23253961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Kuo HC; Jiang YH; Tsai YC; Kuo YC
    Neurourol Urodyn; 2016 Jun; 35(5):609-14. PubMed ID: 25914337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome.
    Nickel JC; Egerdie B; Davis E; Evans R; Mackenzie L; Shrewsbury SB
    J Urol; 2016 Sep; 196(3):747-54. PubMed ID: 26968644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial.
    Jiang YH; Jhang JF; Lee CL; Kuo HC
    Neurourol Urodyn; 2018 Apr; 37(4):1467-1473. PubMed ID: 29331031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intravesical instillation of KRP-116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, double-blind, placebo-controlled, clinical study.
    Yoshimura N; Homma Y; Tomoe H; Otsuka A; Kitta T; Masumori N; Akiyama Y; Niimi A; Mitsui T; Nanri M; Namima T; Takei M; Yamaguchi A; Sekiguchi Y; Kajiwara M; Kobayashi S; Ameda K; Ohashi Y; Sakamoto S; Muraki O; Shishido T; Kageyama S; Kokura K; Okazoe H; Yamanishi T; Watanabe T; Uno T; Ohinata A; Ueda T
    Int J Urol; 2021 May; 28(5):545-553. PubMed ID: 33580603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistochemistry analysis.
    Peng CH; Jhang JF; Shie JH; Kuo HC
    Urology; 2013 Dec; 82(6):1452.e1-6. PubMed ID: 24295265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum Toxin A Injections Into Pelvic Floor Muscles Under Electromyographic Guidance for Women With Refractory High-Tone Pelvic Floor Dysfunction: A 6-Month Prospective Pilot Study.
    Morrissey D; El-Khawand D; Ginzburg N; Wehbe S; O'Hare P; Whitmore K
    Female Pelvic Med Reconstr Surg; 2015; 21(5):277-82. PubMed ID: 25900057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies.
    Wang J; Wang Q; Wu Q; Chen Y; Wu P
    Med Sci Monit; 2016 Sep; 22():3257-67. PubMed ID: 27624897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome.
    Kuo HC
    Int J Clin Pract; 2013 May; 67(5):427-34. PubMed ID: 23574103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O'Leary-Sant Symptom Index Predicts the Treatment Outcome for OnabotulinumtoxinA Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome.
    Kuo YC; Kuo HC
    Toxins (Basel); 2015 Jul; 7(8):2860-71. PubMed ID: 26264022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome.
    Lee CL; Kuo HC
    Toxins (Basel); 2015 Oct; 7(10):4283-93. PubMed ID: 26506388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis.
    Lee CL; Kuo HC
    Pain Physician; 2013; 16(2):109-16. PubMed ID: 23511677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome.
    Chung SD; Kuo YC; Kuo HC
    Pain Physician; 2012; 15(3):197-202. PubMed ID: 22622903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Feasibility of Intravesical Instillation of Botulinum Toxin-A in Hydrogel-based Slow-release Delivery System in Patients With Interstitial Cystitis-Bladder Pain Syndrome: A Pilot Study.
    Rappaport YH; Zisman A; Jeshurun-Gutshtat M; Gerassi T; Hakim G; Vinshtok Y; Stav K
    Urology; 2018 Apr; 114():60-65. PubMed ID: 29307733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.